I think yesterday's letter from FDA was unexpected - my son's Dr. had been talking about it as a done-deal.
"SAN FRANCISCO -- Gilead Sciences Inc. said late Tuesday it received a letter from the Food and Drug Administration informing the company that it cannot approve aztreonam lysine in its current form and an additional clinical study will be required. Gilead had submitted a new drug application for aztreonam lysine for inhalation for people with cystic fibrosis. "Gilead will continue its dialogue with the FDA to determine whether further analyses of existing data could lead to approval, or whether the company will need to conduct the additional study as stated in the letter," said the drug maker."
"SAN FRANCISCO -- Gilead Sciences Inc. said late Tuesday it received a letter from the Food and Drug Administration informing the company that it cannot approve aztreonam lysine in its current form and an additional clinical study will be required. Gilead had submitted a new drug application for aztreonam lysine for inhalation for people with cystic fibrosis. "Gilead will continue its dialogue with the FDA to determine whether further analyses of existing data could lead to approval, or whether the company will need to conduct the additional study as stated in the letter," said the drug maker."